Trials / Active Not Recruiting
Active Not RecruitingNCT04167540
GDNF Gene Therapy for Parkinson's Disease
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Brain Neurotherapy Bio, Inc. · Industry
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | AAV2-GDNF | Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2023-10-17
- Completion
- 2027-06-01
- First posted
- 2019-11-19
- Last updated
- 2025-09-19
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04167540. Inclusion in this directory is not an endorsement.